title: [Maturity onset diabetes of the young (MODY) - screening, diagnostic and therapy].
abstract: Maturity onset diabetes of the young (MODY) is a group of monogenetic diabetes types affecting up to 2% all known diabetics. Transcription factor MODY (HNF1α, HNF4α), the most frequent forms of MODY, allow treatment with sulfonylureas, mutations of glucokinase (GCK-MODY) usually do not require any therapy. Especially in younger patients correct diagnosis of MODY often results in discontinuation of insulin therapy and initiation of a sulfonylurea. Accordingly, in patients with diabetes onset below age of 25 years, with a positive family history for diabetes and negative autoantibodies screening for MODY is recommended.
authors.affiliation: Department für Innere Medizin 1, Medizinische Universität Innsbruck, Innsbruck, Österreich. Susanne.Kaser@i-med.ac.at.|Christian Doppler Labor für Insulinresistenz, Medizinische Universität Innsbruck, Innsbruck, Österreich. Susanne.Kaser@i-med.ac.at.
authors.forename: Susanne
authors.initials: S
authors.lastname: Kaser
authors.affiliation: Interne Abteilung, Konventhospital der Barmherzigen Brüder Linz, Linz, Österreich.
authors.forename: Michael
authors.initials: M
authors.lastname: Resl
mesh_terms: D001317:Austria; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis* / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008403:Mass Screening / Q000592:standards*; D017410:Practice Guidelines as Topic; D013453:Sulfonylurea Compounds / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds
keywords: Diabetes; Glucokinase mutation; Monogenetic; Transcription factors